Fresenius Medical Care — 6.75/10
Fresenius Medical Care (FMS / XTRA:FME) is the world's #1 integrated dialysis franchise. It both operates dialysis clinics (Care Delivery, ~64% of Q1'26 revenue) and manufactures the machines, dialyzers, and consumables those clinics consume (Care Enablement, ~25%), plus a smaller value-based-care payer arm (VBC, ~9%). In the US it co-leads an ~80% two-firm outpatient-dialysis duopoly with DaVita (~37-38% share each), and globally it is #1 in hemodialysis machines and dialyzers, with FMS + Baxter/Vantive controlling more than half the equipment market. It reports in EUR; market data is USD.
The core tension: FMS is a genuine oligopoly leader midway through a high-quality, credible self-help turnaround, but it is fundamentally a cost-out / deleveraging story rather than a growth-leader story. Margins are genuinely expanding (OI ex-SI margin +70 bps YoY in Q1'26), net leverage has fallen 3.4x → 2.5x, and management has a ~83% promise hit-rate with a beat-and-raise pattern. But reported revenue is decelerating (-6% in Q1'26), the core US same-market treatment KPI has not turned, and free cash flow — while positive — has not reclaimed its 2023 peak. A known, quantified TDAPA reimbursement benefit that flattered 2025 rolls off in H2'26, creating a flat-EBIT transition year.
| CEO / CFO | Helen Giza (since Oct 2022) / Martin Fischer | Reported Revenue | Decelerating (-6% Q1'26; organic +4%) |
| Theme | ESRD / dialysis (~5-8% CAGR) | FCF Trajectory | Positive, below 2023 peak |
| Net Leverage | 2.5x (from 3.4x) | FME25 Savings | €804m delivered (vs €500m target) |
| Quality Gate | PASS (0 NOs) | Margin Trend | Expanding |
| Dimension | Score | Weight | Weighted |
|---|---|---|---|
| Financial Trends | 5 | 25% | 1.25 |
| Thematic Exposure | 7 | 35% | 2.45 |
| Management Quality | 8 | 20% | 1.60 |
| Investor Sentiment (Inverted) | 8 | 5% | 0.40 |
| Concerns / Risks | 7 | 15% | 1.05 |
| Composite | 100% | 6.75 |
FMS is a genuine oligopoly leader — the global #1 dialysis franchise and co-leader of an ~80% US outpatient-dialysis duopoly — midway through a high-quality, credible self-help turnaround. It scores 6.75/10 and clears the quality gate cleanly (oligopoly YES, positive/growing FCF YES, management track record YES — 0 NOs, no composite cap).
Quality gate: PASS (0 NOs). Management (Giza/Fischer, ~83% promise hit-rate, beat-and-raise, leverage 3.4x → 2.5x, FME25 €804m delivered) is loudly bullish on the 5008X/HVHDF volume-and-mortality thesis and a low-teens underlying earnings CAGR that a skeptical, mixed sell-side (2 Buy / 3 Hold / 2 Sell) does not believe — a real management-vs-street divergence reinforced by ~EUR 2B of buybacks.
The two things holding the composite to a high-6 sit in the highest-weight dimension (Financial Trends 25%): reported revenue is decelerating/negative (-6% in Q1'26, though largely portfolio pruning / FX / accounting, with organic +4%), the core US same-market treatment KPI has not turned, and FCF — while positive and modestly growing — has not reclaimed its 2023 peak.
The honest characterization is a cheap, deleveraging turnaround, not a leader-in-a-growing-market compounder. The theme grows ~5-8%, but FMS's own reported revenue is flat-to-negative (~+1.5% five-year CAGR) and the core US volume KPI is flat. The bull case is margin and cash recovery — proven — plus a re-rating toward DaVita if the volume thesis validates. The bear case is that the discount to DaVita is deserved given the lower-margin manufacturing drag, slower same-market treatment growth, and execution risk on the largest clinic conversion in company history.
Add the known, quantified, one-year TDAPA reimbursement air-pocket in H2'26 — a combined ~EUR 300m+ benefit rolling off, producing flat 2026 EBIT that masks the low-teens underlying algorithm — and you have a cheaply valued (vs DaVita on EV/EBITDA and P/E) leader whose margin/cash recovery is proven but whose top-line re-acceleration is still "show me." The 6.75 reflects real quality and a genuine sentiment edge, discounted for a top line that has not yet turned.